Effect of Low Dose Oral Vitamin D on Bone Mineral Density Changes in HIV Patients.
A high incidence of vitamin-D deficiency and abnormal bone mineral density (BMD) is reported amongst Human Immunodeficiency Virus (HIV) infected patients. Out study looked at the effect of oral low dose vitamin-D replacement in patients with a known vitamin-D deficiency on levels of vitamin-D, parathyroid hormone (PTH) and Bone Mineral Density (BMD) of hip and spine METHODS: Patients took a daily low dose of 800IU of vitamin-D. The following details were collected on all patients: demographics, CD-D cell count, viral load, fracture risk factors, treatment history, corrected calcium, alkaline phosphatase (ALP), Parathyroid Hormone (PTH) (intact PTH), measured 25(OH)D, inorganic phosphate and BMD of hip and spine at baseline, 12 and 36 months. Our Cohort consisted of 86 patients. Patient details included: mean age 42.8 (+/-7.7) years,48 (55%) females 64 (74%) black African, CD-4 count 440.7 (+/-180.8) cells/dL, plasma VL 1.6 log (+/-2.3) copies/mL, duration of illness 56.9 (+/-34.1) months, plasma VL 1.6 log (+/-2.3) copies/ml, duration of exposure to antiretroviral 41.2 (+/-27.9) months, duration of exposure to antiretroviral 41.2 (+/-27.9) months. At base line there was no difference in BMD of hip or spine was noticed, however a higher PTH (0.001) in patients taking Tenofivir and a lower vitamin-D was noticed in patients taking Efavirenz. After 36 months patients on vitamin D replacement (n=44) had a significant increase in vitamin-D level (15.4 +/-10.4 vs 104.1+/-29.1 p=0.0001), lowerPTH (6.3 +/-3.4 vs 4.4 +/-1.4 p=0.0001) ALP (108.9+/-78.8 vs 90.6+/-45.8 p=0.05) but no change in corrected calcium (2.13 +/-0.1 vs 2.16 +/-0.34 p=0.5) and BMD of spine (1.039+/-0.226 vs.1.027+/-0.211, p=0.77), and BMD of hip (1.020 +/- 0.205 vs. 1.039, p=0.61).In a multivariate logistic regression analysis that included all significant variables, vitamin-D replacement independently was associated with increase in vitamin-D level (OR 2.08, CI 1.03, 4.12, p=0.005), decrease in PTH level (OR 0.53, CI 0.35, 0.82, p=0.04), but not with change in corrected calcium, alkaline phosphatase, BMD of hip or spine. After 36 months of follow up, replacement of low dose once daily oral vitamin-D in treatment experienced HIV infected patients with vitamin-D deficiency can increase vitamin-D level, reduce PTH level without any change in BMD of spine and hip.